Welcome to SynapCell

SynapCell is a biotechnology company providing the CNS drug manufacturing industry with translational drug discovery solutions to reveal the therapeutic potential of their molecules targeting CNS disorders.



Epilepsy solutions

Since 2005 SynapCell has been assessing the efficacy of your drug candidates for epilepsy using surface and deep EEG recording. We use a translational approach combining relevant animal models of different types of epilepsy, protocols performed in clinical conditions, and quantitative results to reveal brain dysfunction and epileptic seizures.


Solutions for other CNS disorders

With a translational approach combining relevant animal models of CNS disorders, protocols performed in clinical conditions and EEG-related technologies to reveal brain activities, SynapCell assesses the effects of your drug candidates in the treatment of CNS disorders with unmet needs.


EEG phenotyping of rodent models

Develop your personalized drug discovery tool using SynapCell’s expertise in the EEG phenotyping of rodent models to improve your insights into the relevance of your therapeutic targets in CNS disorders.

What's new

Twelfth Eilat Conference on new antiepileptic drugs
August 31 – September 3, 2014

Relocated in Madrid, Spain, August 31 – September 3 for this forthcoming edition, the twelfth Eilat Conference on new antiepileptic drugs (AEDs) will be introducing debates as a new feature. These debates are added to the previous format of in-depth progress report on new antiepileptic drugs in different stages of development, as well as conferences presenting new findings on second-generation treatments.

SynapCell will be presenting its solutions based on the MTLE mouse model of chronic epilepsy and their particular adequacy for drug development in the field during the poster session.

It would be a pleasure to meet you there!

More informations on eilatxii.com